O'Shaughnessy Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

O'Shaughnessy Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,928	Closed	-$259K	–	1743
2023 Q3	$259K	Buy	+2,928	New	+$261K	﹤0.01%	1181
2021 Q3	–	Sell	-6	Closed	-$1K	–	2724
2021 Q2	$1K	Hold	6	–	–	﹤0.01%	2383
2021 Q1	$0	Hold	6	–	–	﹤0.01%	2370
2020 Q4	$1K	Sell	6 -12	-67%	-$951	﹤0.01%	1896
2020 Q3	$1K	Sell	18 -38	-68%	-$3.85K	﹤0.01%	1702
2020 Q2	$7K	Buy	56 +41	+273%	+$4.08K	﹤0.01%	1314
2020 Q1	$1K	Hold	15	–	–	﹤0.01%	1197
2019 Q4	$1K	Buy	+15	New	+$1.13K	﹤0.01%	1718

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

O'Shaughnessy Asset Management's BMRN Position: Q4 2023 in Review

O'Shaughnessy Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 2,928 shares — an estimated $259K sold.

O'Shaughnessy Asset Management first reported a position in BMRN in Q4 2019 and held it in 8 quarters. The position peaked at $259K in Q3 2023. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

O'Shaughnessy Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
O'Shaughnessy Asset Management sold 2,928 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $259K.
O'Shaughnessy Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 8 quarters.
O'Shaughnessy Asset Management's BioMarin Pharmaceuticals position peaked at $259K in Q3 2023.
547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2023, filed 9 Feb 2024.